Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial
Study context
- Population
- Adult patients with sickle cell disease (SCD) with elevated tricuspid regurgitant jet velocity (TRV) and/or chronic kidney disease, considered to be at high risk of deathparticipants randomized between 2020 and 2025
- Participants
- 173 patients
- Planned comparison
- RBCX plus standard of care vs standard of care alone
- Primary endpoint
- number of SCD acute health care encounters or death
- Follow-up
- Over 13 months
Methodological details23 sites across 3 countries
- 23 sites across 3 countries
No results yet. This paper sets out the design of a trial; its results are to come.
Baseline
Baseline characteristics
- Mean (SD) age
- 45.8 (11.8) years
- Female
- 54%
- Average TRV
- 2.8 (0.5) m/s
- TRV between 2.5 to 2.9 m/sec
- 45.9%
- TRV ≥ 3.0 m/sec
- 28.1%
- Median (Q1, Q3) eGFR
- 60 (36, 110) mL/min/1.73 m²
- Median (Q1, Q3) 6-minute walk test distance
- 375 meters (309, 439)
- Median daily steps
- 3,728 (2,187, 5,821)
- Median (Q1, Q3) pain episodes in the year prior to randomization
- 2 (1, 5)
Original publication
Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial. Am Heart J. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →